News

PsA, PsC do not affect total hip replacement outcomes


 

FROM ARTHRITIS & RHEUMATOLOGY

References

Neither psoriatic arthritis (PsA) nor cutaneous psoriasis (PsC) is an independent predictor of poor postoperative pain or function following a total hip arthroplasty, according to the results of a case-control study by Dr. Lisa A. Mandl and her colleagues.

The study’s participants underwent surgery between May 1, 2007, and Dec. 31, 2010, in a center that performs more than 4,300 THAs annually. All subjects lived for at least 2 years after their operations. The researchers compared pre- and postoperative data from patients in the following three categories: those with PsA, those with PsC without evidence of inflammatory arthritis, and those with osteoarthritis (OA). Patients with OA comprised the control group, which excluded any patient who self-reported a history of PsA, rheumatoid arthritis, lupus erythematosus, or any other systematic rheumatic disease, or who had documentation of skin psoriasis. The researchers acquired postoperative self-report data from 47 PsA patients, 106 PsC patients, and 864 OA patients. Seventeen percent of patients submitted information on their status at 1 year, 69% at 2 years, and 14% at 3-5 years.

Dr. Lisa A. Mandl

Dr. Lisa A. Mandl

The primary outcomes of interest were postoperative pain and function, which were assessed via the Hip Osteoarthritis Outcome Score (HOOS), from which the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) was derived.

There were no statistically significant differences in postoperative WOMAC pain or function scores between the three groups of patients (P = .78 and .96, respectively). The mean pain scores were 14.9, 6.1, and 15.8 for patients with PsA, PsC, and OA, respectively. These patients’ mean function scores were 16.3, 19.6, and 18.8 for the PsA, PsC and OA groups, respectively.

Overall levels of satisfaction with the surgery were similar among the three groups (P = .54). Ninety-three percent of the PsA patients, 79% of the PsC patients, and 84% of the OA patients were “very satisfied” with their total hip arthroplasty. Between 1% and 3% of each group reported being “very dissatisfied” with their surgery. The researchers found that extent of skin disease was not associated with worse postoperative pain or function.

“Further work needs to be done to better understand the interplay of disease activity and quality of life on the outcomes of [total hip arthroplasty] in PsA and PsC,” they wrote.

Read the report in Arthritis & Rheumatology (doi: 10.1002/art.39431).

klennon@frontlinemedcom.com

Recommended Reading

Biologic treatment for psoriasis found to have CVD benefits
MDedge Dermatology
As psoriasis maintenance therapy, step-down matched full-dose etanercept for quality of life measures
MDedge Dermatology
Simple screening tool can help detect psoriatic arthritis
MDedge Dermatology
Higher risk of arrhythmia in psoriasis patients
MDedge Dermatology
Interviews with psoriasis patients reveal disease hardships
MDedge Dermatology
Psoriasis patients more likely to have type D personalities
MDedge Dermatology
Nail psoriasis therapies lack supporting evidence
MDedge Dermatology
WCD: Look for TNF inhibitor–induced psoriasis in kids
MDedge Dermatology
Methotrexate ups risk of liver abnormalities, but not serious hepatic events
MDedge Dermatology
Tissue-based treatment could improve psoriatic arthritis outcomes
MDedge Dermatology